Skip to main content
. 2016 Dec 6;112(3):447–457. doi: 10.1038/ajg.2016.500

Figure 3.

Figure 3

Occurrence of adverse events in the AspireAssist group. Time course of the adverse advents that occurred at a prevalence rate 5% or more during the 52-week study in the AspireAssist group.